Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma Differentiation by New miRNA Biomarker Panel
Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit
Pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CC) are two highly aggressive malignant tumor types, associated with poor prognosis. Owing to their overlapping immunohistochemical profiles and morphological similarity, they are virtually indistinguishable histologically. Due to the lack of specific clinical symptoms, they are rarely detected at an early stage and are usually fatal within months of diagnosis. Immunohistochemical biomarkers supporting pathologists in the differential diagnosis of PDAC and CC may be helpful in order to better understand the disease, define specific diagnostic tools and highlight relevant novel targets for pharmacological treatments. Recent advances in the sensitive and quantitative detection of microRNAs (miRNAs) in human tumors are making miRNAs as promising noninvasive biomarkers for diagnostic and prognostic assessments of pancreatic cancer and as targets for therapy. Although numerous techniques are available for gaining information about miRNA signatures, in situ hybridization (ISH) technique is the only method that allows direct assessment of the distribution of particular miRNAs at the cellular and subcellular levels.
BioGenex is pleased to launch two Super Sensitive Nucleic Acid miRNA ISH (SSNA miRNA ISH) probes and automated systems for differentiation of CC and PDAC. BioGenex SSNA miRNA ISH probes give consistent, reproducible and reliable outcomes. Adaptation of automated processing using Xmatrx® in ISH procedure eliminates error-prone manual steps and greatly increases reproducibility, accuracy, and sensitivity of the test results.
BioGenex end-to-end miRNA solution including Xmatrx® automated systems and miRNA ISH panel probes were used to successfully identify a group of differentially expressed miRNAs in CC and PDAC, which have potential as biomarkers for diagnostic, prognostic and therapeutic applications. miRNA expression profile was evaluated in intra/ extrahepatic CCs and PDACs. miR-196a and miR-216a were downregulated in PDACs as compared with CCs. These findings have also demonstrated the feasibility of in situ evaluation in the paraffin-embedded tissue where the ability to morphologically differentiate cancer and benign cells are retained.
Please click on below links to download Biomarker Panel and Application Note for
Cholangiocarcinoma and Pancreatic Cancer Differentiation.
BioGenex also has an extensive catalog of over 240 unique miRNA probes